CG Oncology (CGON) Preferred Dividend Payments (2023)
CG Oncology posted quarterly Preferred Dividend Payments of -$12.4 million for Q4 2023, down 3133.17% on a QoQ basis from $410000.0 in Q3 2023.
CG Oncology (CGON) has 1 years of Preferred Dividend Payments data on file, last reported at -$12.4 million in Q4 2023.
- For the quarter ending Q4 2023, Preferred Dividend Payments changed N/A year-over-year to -$12.4 million; the trailing twelve-month figure through Dec 2024 stood at -$12.4 million (down 175.38% YoY), and the FY2023 full-year result was $410000.0, changed N/A from the prior year.
- Preferred Dividend Payments for Q4 2023 stood at -$12.4 million, down from $410000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $3.8 million in Q2 2023 and bottomed at -$12.4 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | 410,000.00 |
| Jun 30, 2023 | 3.78 Mn |
| Mar 31, 2023 | 3.73 Mn |